You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
潤達醫療(603108.SH):杭州潤達擬收購上海潤林41%股權
格隆匯 12-25 21:39

格隆匯12月25日丨潤達醫療(603108.SH)公佈,公司全資子公司杭州潤達醫療管理有限公司(以下簡稱“杭州潤達”或“受讓方”)擬與上海潤達盛瑚投資管理中心(有限合夥)(以下簡稱“潤達盛瑚”)、上海潤祺投資管理中心(有限合夥)(以下簡稱“潤祺投資”)、江蘇康克生物技術有限公司(以下簡稱“江蘇康克”)、成都坤洋實業發展有限公司(以下簡稱“成都坤洋”)、深圳市樹輝投資諮詢有限公司(以下簡稱“深圳樹輝”)五方簽署關於上海潤林醫療科技有限公司(以下簡稱“上海潤林”或“標的公司”)的股權轉讓協議。擬約定杭州潤達合計使用自籌資金人民幣1.33億元以現金方式受讓潤達盛瑚、潤祺投資、江蘇康克、成都坤洋及深圳樹輝分別持有上海潤林10.00%、10.00%、7.14%、6.93%及6.93%的股權。本次交易完成後,杭州潤達將持有上海潤林56%的股權。

上海潤林圍繞以病理檢驗為中心的分子診斷、免疫組化、數字病理、信息化服務等病理實驗室綜合服務業務,構建了一支專業化的綜合服務團隊,可以為病理實驗室提供包括HPV檢測、液基細胞學、分子診斷、免疫組化、切片掃描等病理檢測全門類的產品及服務,還可以通過提供整體綜合解決方案充分提升病理實驗室運營效率、管理水平。上海潤林服務區域覆蓋華東、華南和西部地區,以上海市、江蘇省、廣東省、四川省、新疆自治區等地客户為主。本次交易後,上市公司將能夠有效的利用已有的病理實驗室綜合服務團隊以及標的公司相關專業能力,進一步加強在病理實驗室綜合服務領域的佈局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account